ZA202301801B - Inhibitors of sarm1 - Google Patents
Inhibitors of sarm1Info
- Publication number
- ZA202301801B ZA202301801B ZA2023/01801A ZA202301801A ZA202301801B ZA 202301801 B ZA202301801 B ZA 202301801B ZA 2023/01801 A ZA2023/01801 A ZA 2023/01801A ZA 202301801 A ZA202301801 A ZA 202301801A ZA 202301801 B ZA202301801 B ZA 202301801B
- Authority
- ZA
- South Africa
- Prior art keywords
- sarm1
- inhibitors
- treating
- present disclosure
- disclosure provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069408P | 2020-08-24 | 2020-08-24 | |
| US202163142398P | 2021-01-27 | 2021-01-27 | |
| PCT/US2021/047093 WO2022046606A1 (en) | 2020-08-24 | 2021-08-23 | Inhibitors of sarm1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202301801B true ZA202301801B (en) | 2024-09-25 |
Family
ID=77775005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/01801A ZA202301801B (en) | 2020-08-24 | 2023-02-14 | Inhibitors of sarm1 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12043613B2 (enExample) |
| EP (1) | EP4200293A1 (enExample) |
| JP (2) | JP7349046B2 (enExample) |
| KR (1) | KR20230057396A (enExample) |
| AU (2) | AU2021333558C1 (enExample) |
| BR (1) | BR112023002575A2 (enExample) |
| CA (1) | CA3189181A1 (enExample) |
| CL (1) | CL2023000525A1 (enExample) |
| CO (1) | CO2023001975A2 (enExample) |
| CR (1) | CR20230113A (enExample) |
| DO (1) | DOP2023000038A (enExample) |
| EC (1) | ECSP23012981A (enExample) |
| IL (1) | IL300586A (enExample) |
| MX (1) | MX2023002256A (enExample) |
| PE (1) | PE20230737A1 (enExample) |
| TW (2) | TW202334117A (enExample) |
| WO (1) | WO2022046606A1 (enExample) |
| ZA (1) | ZA202301801B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12083114B2 (en) | 2018-12-19 | 2024-09-10 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 in combination with neuro-protective agents |
| WO2022031736A1 (en) | 2020-08-04 | 2022-02-10 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| CN116438171A (zh) | 2020-09-16 | 2023-07-14 | 努拉生物公司 | 作为sarm1抑制剂的取代的吡啶衍生物 |
| EP4376840A4 (en) | 2021-07-28 | 2025-05-21 | Nura Bio, Inc. | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS |
| CN120456910A (zh) * | 2022-07-21 | 2025-08-08 | 艾美力克斯制药股份有限公司 | 寡核苷酸组合物及其方法 |
| WO2024125624A1 (en) * | 2022-12-15 | 2024-06-20 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
| CN121002009A (zh) | 2023-01-24 | 2025-11-21 | 达萨玛治疗公司 | 作为sarm1抑制剂的哒嗪类物 |
| WO2024222835A1 (en) * | 2023-04-27 | 2024-10-31 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
| CN119219603A (zh) * | 2023-06-28 | 2024-12-31 | 科辉智药(深圳)新药研究中心有限公司 | Sarm1酶活性抑制剂及其用途 |
| WO2025045746A1 (en) * | 2023-08-25 | 2025-03-06 | F. Hoffmann-La Roche Ag | Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders |
| WO2025049184A1 (en) | 2023-08-25 | 2025-03-06 | Eli Lilly And Company | (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate |
| WO2025076088A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Lactams for use as sarm1 inhibitors |
| WO2025076017A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Carbamates for use as sarm1 inhibitors |
| WO2025157895A1 (en) | 2024-01-25 | 2025-07-31 | UCB Biopharma SRL | Pyrrolidinone derivatives |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11193281A (ja) | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンａ３受容体拮抗剤およびチアゾール化合物 |
| US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| ATE466855T1 (de) | 2002-10-30 | 2010-05-15 | Vertex Pharma | Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen |
| EP1581222A2 (en) | 2003-01-02 | 2005-10-05 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| DE602005020611D1 (de) | 2004-04-28 | 2010-05-27 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
| JP2008524233A (ja) | 2004-12-16 | 2008-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | 炎症性疾患、増殖性疾患および免疫介在性疾患の治療のためのｔｅｃファミリータンパク質キナーゼのインヒビターとして有用なピリド−２−オン |
| CN101472921B (zh) | 2006-06-28 | 2012-10-10 | Aska制药株式会社 | 吡啶基异*唑衍生物 |
| US20100105664A1 (en) | 2006-09-21 | 2010-04-29 | Richard Heng | Organic compounds |
| JP2011506560A (ja) | 2007-12-20 | 2011-03-03 | ノバルティス アーゲー | Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体 |
| WO2009080705A2 (en) | 2007-12-20 | 2009-07-02 | Novartis Ag | Bis-thiazole derivatives, process for their preparation and their use as medicaments |
| TW201004941A (en) | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
| US8785468B2 (en) | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| US20120328629A1 (en) | 2011-06-24 | 2012-12-27 | University Of Miami | Therapeutic Applications Targeting SARM1 |
| US9284310B2 (en) | 2012-11-03 | 2016-03-15 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
| EP2934536B1 (en) | 2012-12-19 | 2017-09-27 | Merck Sharp & Dohme Corp. | FACTOR IXa INHIBITORS |
| RU2570907C2 (ru) | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
| EP3076789A4 (en) | 2013-12-04 | 2017-11-22 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| EP4091622A1 (en) | 2016-08-16 | 2022-11-23 | Henry Ford Health System | Compositions for the treatment of chemotherapy-induced neuropathic pain |
| EP3515426A1 (en) | 2016-09-24 | 2019-07-31 | Washington University | INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF |
| UY37512A (es) | 2016-12-09 | 2019-04-30 | Vertex Pharma | Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga |
| JP2020503312A (ja) * | 2016-12-22 | 2020-01-30 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 置換１，２，４−チアジアゾリルピロロンおよび１，２，４−チアジアゾリルヒダントイン、ならびにその塩、ならびにその除草剤としての使用 |
| EP3558976A1 (de) | 2016-12-22 | 2019-10-30 | Bayer CropScience Aktiengesellschaft | Substituierte azolylpyrrolone und azolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| AU2018388406B2 (en) * | 2017-12-22 | 2023-07-06 | HiberCell Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| MA52812A (fr) * | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
| MA52809A (fr) | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
| CA3102645A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| US12084436B2 (en) | 2019-01-30 | 2024-09-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7289375B2 (ja) | 2019-06-06 | 2023-06-09 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| CA3141404A1 (en) | 2019-06-14 | 2020-12-17 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| WO2021013721A1 (de) | 2019-07-22 | 2021-01-28 | Bayer Aktiengesellschaft | 5-amino substituierte pyrazole und triazole als schädlingsbekämpfungsmittel |
| CA3150878A1 (en) | 2019-09-12 | 2021-03-18 | Jonathan Bentley | Inhibitors of sarm1 |
| AU2020380395A1 (en) | 2019-11-05 | 2022-05-26 | Dermira, Inc. | MrgprX2 antagonists for the treatment of inflammatory disorders |
| JP7490781B2 (ja) | 2020-01-07 | 2024-05-27 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| CN116075511B (zh) | 2020-04-09 | 2024-10-29 | 达萨玛治疗公司 | 作为sarm1抑制剂的稠合吡唑衍生物 |
| ES3049432T3 (en) | 2020-04-09 | 2025-12-16 | Disarm Therapeutics Inc | Indazole derivatives as inhibitors of sarm1 |
| WO2022031736A1 (en) | 2020-08-04 | 2022-02-10 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
-
2021
- 2021-08-20 TW TW111144632A patent/TW202334117A/zh unknown
- 2021-08-20 TW TW110130799A patent/TWI786777B/zh active
- 2021-08-23 WO PCT/US2021/047093 patent/WO2022046606A1/en not_active Ceased
- 2021-08-23 IL IL300586A patent/IL300586A/en unknown
- 2021-08-23 MX MX2023002256A patent/MX2023002256A/es unknown
- 2021-08-23 CR CR20230113A patent/CR20230113A/es unknown
- 2021-08-23 KR KR1020237009643A patent/KR20230057396A/ko active Pending
- 2021-08-23 JP JP2023513172A patent/JP7349046B2/ja active Active
- 2021-08-23 EP EP21770372.7A patent/EP4200293A1/en active Pending
- 2021-08-23 US US17/408,956 patent/US12043613B2/en active Active
- 2021-08-23 CA CA3189181A patent/CA3189181A1/en active Pending
- 2021-08-23 BR BR112023002575A patent/BR112023002575A2/pt unknown
- 2021-08-23 PE PE2023000530A patent/PE20230737A1/es unknown
- 2021-08-23 AU AU2021333558A patent/AU2021333558C1/en active Active
-
2023
- 2023-02-14 ZA ZA2023/01801A patent/ZA202301801B/en unknown
- 2023-02-22 CL CL2023000525A patent/CL2023000525A1/es unknown
- 2023-02-22 CO CONC2023/0001975A patent/CO2023001975A2/es unknown
- 2023-02-23 EC ECSENADI202312981A patent/ECSP23012981A/es unknown
- 2023-02-23 DO DO2023000038A patent/DOP2023000038A/es unknown
- 2023-09-08 JP JP2023145779A patent/JP7756130B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203373A patent/AU2024203373A1/en active Pending
- 2024-06-19 US US18/747,889 patent/US20240376083A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023002256A (es) | 2023-03-17 |
| KR20230057396A (ko) | 2023-04-28 |
| AU2021333558A1 (en) | 2023-03-02 |
| AU2021333558C1 (en) | 2024-06-20 |
| CO2023001975A2 (es) | 2023-03-07 |
| US20220056013A1 (en) | 2022-02-24 |
| JP2023535236A (ja) | 2023-08-16 |
| US20240376083A1 (en) | 2024-11-14 |
| JP7349046B2 (ja) | 2023-09-21 |
| JP7756130B2 (ja) | 2025-10-17 |
| TW202214597A (zh) | 2022-04-16 |
| IL300586A (en) | 2023-04-01 |
| TWI786777B (zh) | 2022-12-11 |
| EP4200293A1 (en) | 2023-06-28 |
| CL2023000525A1 (es) | 2023-09-15 |
| AU2021333558B2 (en) | 2024-02-22 |
| CR20230113A (es) | 2023-04-14 |
| AU2024203373A1 (en) | 2024-06-13 |
| ECSP23012981A (es) | 2023-03-31 |
| WO2022046606A1 (en) | 2022-03-03 |
| TW202530197A (zh) | 2025-08-01 |
| US12043613B2 (en) | 2024-07-23 |
| CA3189181A1 (en) | 2022-03-03 |
| BR112023002575A2 (pt) | 2023-03-07 |
| DOP2023000038A (es) | 2023-03-15 |
| PE20230737A1 (es) | 2023-05-03 |
| JP2024016014A (ja) | 2024-02-06 |
| TW202334117A (zh) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202301801B (en) | Inhibitors of sarm1 | |
| MY206478A (en) | Inhibitors of sarm1 | |
| WO2020252229A3 (en) | Inhibitors of sarm1 | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| MX2021003819A (es) | Moduladores de alfa-1 antitripsina. | |
| MX2022010944A (es) | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. | |
| CR20240296A (es) | Inhibidores parp1 | |
| MX2024004993A (es) | Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| ZA202105742B (en) | Modulators of malat1 expression | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| MX2020010721A (es) | Moduladores de la expresion de ezh2. | |
| WO2021076817A3 (en) | Methods and compositions related to treatment and prevention of cancer by inhibition of dgat1 and dgat2 | |
| MX2025003571A (es) | Inhibidores de tead y metodos de uso de los mismos | |
| WO2021102359A3 (en) | Taspase1 inhibitors and uses thereof | |
| MX2024012789A (es) | Inhibidores de fosfoinositida 3-cinasa alfa (pi3kalfa) | |
| WO2023034914A3 (en) | Methods for the prevention and treatment of synucleinopathies | |
| WO2022006377A3 (en) | Heterocyclic inhibitors of rho gtpases for the treatment of disease | |
| PH12022550572A1 (en) | Method for treating mood disorders | |
| MX2020010156A (es) | Inhibidores de la secrecion de proteina cdp. | |
| WO2025189072A8 (en) | Compositions and methods for inhibiting kinases | |
| MX2024000302A (es) | Nanoparticulas para tratamiento contra el cancer. | |
| PH12022550608A1 (en) | Compositions for use in inhibiting src kinase and treating and preventing associated disorders |